Dr. Reddy's Laboratories Q1 2027 Earnings Call Transcript
Dr. Reddy's Laboratories reported a 5.6% revenue decline and an EBITDA margin of 12.5% for Q1 FY2027, primarily due to lower lenalidomide revenues and a INR 240 crore provision for inventory and costs related to semaglutide API challenges. However, the underlying base business, excluding lenalidomide, showed healthy double-digit growth across key geographies including North America, supported by new product launches and favorable currency movements. The earnings call featured CFO Mannam Venkatanarasimham, CEO Erez Israeli, and IR lead Aishwarya Sitharam, with participation from analysts at BofA Securities, Macquarie, BNP Paribas, HSBC, Nomura, and others. Financial figures were translated using a rate of INR 94.66 to the USD as of June 30, 2026.
Editorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page itself is projected from evidence records.
- Current automated evidence projection